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The latest guidelines from the National Institute for Health and Care Excellence 
(NICE) for assisted conception (NICE CG156, 2013) recommend that people 
experiencing unexplained infertility should no longer be offered stimulated intra-
uterine insemination (IUI) as a first-line treatment, but rather be directed towards IVF 
treatment, or alternatively be left to expectant management (EM). NICE has 
acknowledged that the cited evidence leading to this decision was not sufficiently 
robust. As such, we are concerned that accordance with these new NICE guidelines 
may result in people with no identifiable cause of their infertility being prematurely 
referred for IVF treatment. IVF constitutes a more invasive and expensive treatment 
process, which also represents an additional and unnecessary cost pressure to the 
National Health Service. There is a longstanding need for a robust clinical trial to 
resolve the uncertainty as to whether one treatment is more appropriate than 
another. Until such data is available, we suggest that provision of stimulated IUI, in 
centres achieving a satisfactory live birth rate, represents a significant cost-saving to 
those commissioning fertility services, with lower risks to people treated. 
 
Introduction 
This manuscript aims to highlight some basic concerns regarding an aspect of recent 
guidance by the National Institute for Health and Care Excellence (NICE) for assisted 
conception. NICE is a well-respected public body which aims to improve outcomes for 
people using the National Health Service (NHS) and other public health and social care 
services. As such, NICE guidance may be adopted by the NHS, local authorities, 
commissioners, employers, voluntary groups and anyone else involved in delivering care 
or promoting wellbeing. NICE reviews available evidence and gives advice accordingly, 
including consideration of health economics. In the absence of robust evidence that a 
specific treatment is effective, NICE has historically concluded that there is no evidence 
to support implementation of that treatment.   
 Our concern is with regard to the NICE decision to cease the recommendation of 
stimulated IUI (intra-uterine insemination) as a first-line treatment for people with no 
identifiable cause of their infertility. Stimulated IUI therapy has been used extensively 
and successfully for many years. However, there is wide variation in various aspects of 
the IUI process, including the type of people who are offered treatment, the type of 
ovarian stimulation prescribed, and threshold levels for sperm quality. As a result, IUI 
success rates, measured as live births per cycle started, can vary significantly. 
It is not the intention of this manuscript to make the case for stimulated IUI as a first-line 
treatment for couples with unexplained infertility, but rather, to demonstrate that in these 
guidelines NICE did not make a sufficiently robust case to warrant the rejection of 
stimulated IUI. It is of interest that since the publication of the guideline 
recommendations, only a small proportion of UK clinics have made significant changes 
to their practice by reducing the number of IUI cycles or restricting the clinical indications 
for IUI (Kim, Child, & Farquhar, 2015).  With this in mind, we consider that the NICE 
consultation’s conclusion in terms of the direction of future guidance should have been to 
maintain the status quo until such time as more robust data is made available.   
 
The evidence against stimulated IUI 
The rejection of stimulated of IUI relied heavily on just four key studies by Bhattacharya 
et al. (2008), Goverede et al. (2000), Steures et al. (2006) and Tummon, Asher, Martin, 
& Tulandi, (1997).  NICE has consistently classified this underpinning evidence as “low 
quality”, i.e. confidence in the effect estimate is limited (Balshem et al., 2011). The 
evidence is also somewhat contradictory since only two studies clearly reject IUI and one 
of these lacks validity since it describes couples undergoing unstimulated IUI.   
The earliest of these studies (Tummon et al., 1997) compared 311 cycles from 103 
couples, who were diagnosed with unexplained infertility and also associated minimal or 
mild endometriosis. A live birth rate (LBR) of 11.0% (14/127) was recorded for stimulated 
IUI compared to 2.2% (4/184) for expectant management (EM), giving an odds ratio of 
5.6 (95% confidence interval 1.8 to 17.4) in favour of superovulation and IUI. 
The next study (Goverede et al., 2000) directly compared stimulated IUI versus IVF for 
the treatment of unexplained infertility.  A pregnancy rate (PR) per cycle of 8.7% was 
recorded for the IUI group (n=85), which was lower than for the IVF group at 12.2% 
(n=87). However, the cumulative PR for IVF was not significantly better than that for IUI, 
and couples in the IVF group were significantly more likely than those in the IUI group to 
give-up rather than embark upon repeat treatments. They concluded that for the couples 
treated, IUI offered the same likelihood of successful pregnancy as IVF, and was a more 
cost-effective approach. According to this study, costs per pregnancy resulting in at least 
one live birth were approximately three times higher after IVF compared to after IUI. 
Today, some 15 years after this study, little has changed in this cost ratio. 
The randomised trial by Steures et al. (2006) compared IUI with EM, and should be 
viewed with caution. We feel that this study cannot be relied upon to be a useful 
comparator as their cohort included people with tubal pathology (e.g. one-sided tubal 
occlusion and hence not having unexplained infertility) and some treated with 
clomiphene citrate.  Furthermore, the PR per cycle started was 6.5% with an ongoing PR 
of 4.1%, one of the lowest-ever published success rates.  A comparison with the most 
recently published IUI data from the Human Fertilisation and Embryology Authority 
(HFEA) further demonstrates how poor their IUI PR was (Table 1).  However, we accept 
 the HFEA data is observational and collected for legal reasons, and therefore does not 
include sufficient clinical data to be informative about outcomes in individual 
circumstances including clinic-specific results.  Furthermore, we accept the strengths of 
randomised trials are superior to observational data in minimising bias, and also that 
cumulative pregnancy rates can be more revealing than pregnancy rates per cycle.  In 
defence of the Steures study, after three years follow-up, 73% couples had an ongoing 
pregnancy rate in the IUI group, compared to 72% couples in the EM group, with the EM 
group requiring less medical interventions and cost (Custers et al., 2012).  
 
The fourth study also compared IUI with EM (Bhattacharya et al., 2008).  However, this 
study investigated IUI in people without any exogenous drug stimulation, and cannot be 
effectively used to compare against couples having stimulated IUI, as this is not 
comparing ‘like with like’.  This study also included couples with a mild male factor and 
mild endometriosis.  
In conclusion, it seems that only one paper has been used to reject the use of 
superovulation and IUI for the treatment of unexplained infertility for NICE CG156.  
Furthermore, the cited study not only carried relatively low success rates per cycle, but 
was also carried out in people who did not meet the criteria for unexplained infertility.  
 
Health economics profile 
GD156 states that while the health economic analysis showed that IUI could be cost-
effective, there were no apparent health benefits and indeed there were potentially 
increased risks with IUI (with or without stimulation) when compared with an alternative 
strategy of EM.  Therefore the GDG concluded that considerable resources could be 
saved and used elsewhere if IUI was not offered.  
However, the health economics study relied heavily on an economic evaluation 
(Wordsworth et al., 2011), based on the data from one RCT comparing EM with IUI as 
first-line treatments for unexplained infertility and reviewed above (Bhattacharya et al., 
2008).  This study concluded that IUI, whilst being a more expensive treatment than EM, 
did not offer better live birth rates and therefore was unlikely to represent a cost-effective 
use of NHS resources. The economic analysis made some significant assumptions: 
firstly, that the parent study (Bhattacharya et al., 2008) was truly a study of unexplained 
infertility; and secondly, that it was a valid comparison in terms of cost-benefit between 
this and a stimulated IUI service which carried a higher success rate.  The economic 
profile was modelled on a service which provided a live birth rate (LBR) of 22% after a 
mean of 3.4 cycles of unstimulated treatment (LBR 6.5% per cycle). Interestingly, the 
authors also stated that with a modest increase in LBR from 22% to 27%, unstimulated 
IUI becomes cost-effective.  As there was sufficient uncertainty associated with the 
inclusion criteria and with the IUI timing (reliant on compliance in the use of ovulation 
prediction kits), it would be reasonable to assume that even in unstimulated IUI, this LBR 
could easily increase.  More importantly, the economic analysis used to reject IUI as a 
cost-effective treatment was based on unstimulated treatment only.  Yet this study was 
highly influential on the GD156.   
As far as we are aware, there is no published economic analysis comparing EM with 
stimulated IUI, other than a theoretical mathematical modelling based on estimates from 
a hypothetical cohort of subfertile couples (Pashayan, Lyratzopoulos, & Mathur, 2006). 
This modelling did not use population-based data on the effectiveness of stimulated IUI 
 but rather data from a single local centre.  If a cost-benefit analysis were to be 
undertaken, then optimally it would be prospective and multi-centre to provide confirmed 
data with full consensus to ensure:  
a. The IUI process is in line with accepted best practice 
b. The stimulation and monitoring regime is aimed at maximising success whilst 
guarding against multiple pregnancies 
c. Inclusion is restricted to people with unexplained infertility  
d. The cost of laboratory and clinical processes is fully accounted for. 
From the citations provided within the NICE consultation, there is no assurance of any of 
the points raised above. Rather, the data included people with both female and male 




The risk of multiple pregnancies is often cited as a reason to be cautious with stimulated 
IUI (Bhattacharya et al., 2008) and in this case has been used as reason to reject it. 
However, on this matter it seems the NICE consultation document was contradictory. 
The evidence statement reads as follows: 
“Multiple births - No evidence reported” 
“Multiple pregnancies - Low quality evidence from one study showed there were no 
significant differences in the number of multiple pregnancies with the use of IUI without 
ovarian stimulation when compared with expectant management.”  
This second point also emphasised in a Cochrane review on the use of IUI for people 
with unexplained infertility which quotes the need for further robust evidence (Veltman-
Verhulst, Cohlen, Hughes, & Heineman, 2012).  One could therefore argue that there is 
insufficient evidence to reject IUI over EM.  
 
The use of IVF for unexplained infertility 
NICE provides no direct evidence to make the leap from stimulated IUI to IVF as a first-
line treatment after a period of EM, accepting that CG156 does not recommend IVF in 
people with fewer than two years of unexplained infertility. Some of the co-authors of 
studies cited earlier conducted a Cochrane review (Pandian, Gibreel, & Bhattacharya, 
2012) comparing the use of IVF with IUI for unexplained infertility but were unable to 
draw firm conclusions either way. Furthermore, Custers et al. (2011) concluded that for 
people with unexplained or even mild male infertility, one cycle of stimulated IVF with 
elective single embryo transfer might be as effective as three cycles of stimulated IUI as 
primary treatment.   
 Additional support in favour of stimulated IUI has recently been presented by Bensdorp 
et al. (2015). This Dutch group performed a multicentre (17 clinics), open label, three 
arm, parallel group, randomised controlled non-inferiority trial, to compare IVF with a 
single embryo transfer, IVF in a modified natural cycle and stimulated IUI in couples with 
unexplained or mild male subfertility.  Both IVF groups were considered non-inferior to 
the IUI group, with comparable times to pregnancy and rates of multiple pregnancy 
(<7%) in all arms. A subsequent publication from the same team concluded that both IVF 
strategies were significantly more expensive when compared with stimulated IUI, without 
being significantly more effective (Tjon-Kon-Fat et al., 2015) 
Finally, IVF not only constitutes a more invasive treatment process involving higher 
dosage of controlled ovarian hyperstimulation, anaesthesia and oocyte aspiration 
medical procedures with their associated risks for the treated individual (risk factors that 
were also considered by Bensdorp et al. 2015), but there are also controversial 
suggestions that there are may be an increased risk in imprinting disorders for 
subsequent generations suggested to be caused by the embryo culture in vitro 
(Lazaraviciute, Kauser, Bhattacharya, Haggarty, & Bhattacharya, 2014). This may lead 
some to also consider that lower-technology treatment should be a first-line choice, as 
no such risks have been reported or hypothesised for children conceived through IUI.  
However, it is acknowledged that the extent to which birth defects after infertility 
treatment may be explained by underlying parental factors is uncertain (Davies et al., 
2012). 
 
A key role for diagnostic laboratory standards 
One important factor that is missing from all of the above studies is detailed 
information on the male partner, specifically in terms of the accepted levels for IUI 
and the accuracy of his semen analysis. In the recent NICE quality standard QS73 
(NICE, 2014), semen analysis is recognised as the primary assessment tool for male 
fertility potential. In QS73, NICE states that: 
“The accuracy of the result is dependent on following accredited methods of analysis 
that are regularly audited and subject to quality control. Variations in laboratory 
techniques significantly influence the reliability of the results of semen analysis. This 
may lead to a longer process for investigating male infertility, and possibly to 
inappropriate treatment” 
The United Kingdom Accreditation Service (UKAS) now provides a challenging 
accreditation process for andrology laboratories to a recognised international medical 
laboratory standard, ISO 15189:2012. We believe that to ensure precision and 
accuracy in diagnostic andrology, all UK semen analyses should be performed in 
laboratories which have attained the ISO 15189:2012 standard and this should be a 
pre-requisite for aligning people to a specific treatment modality.  
With direct relevance to this issue, the recent British Fertility Society Policy and 
Practice document (Tomlinson, Lewis, & Morroll, 2013) highlighted the impact that 
sperm quality has on treatment outcome:  when optimum numbers of highly motile 
sperm are used for artificial insemination, satisfactory PRs are achieved. 
 
Conclusion 
 In conclusion, there is general agreement between the authors of this document and 
NICE CG156 that there is a clear need for more robust data on stimulated IUI from both 
economic and good clinical practice perspectives. . Publications are emerging that 
criticise the guidelines (e.g. Bahadur, Ilahibuccus, Al-Habib, & Okolo, 2015; Peeraer et 
al., 2015). Furthermore, the low proportion of clinics that are adhering to the 
recommendation to reject IUI as a first-line treatment provides further evidence that this 
advice has not be well received (Kim et al., 2015).As a final consideration, recent 
economic analyses suggests that if only cost per live birth is considered then IUI 
continues to be better value that IVF (Moolenaar et al., 2015; Tjon-Kon-Fat et al., 2015), 
even without taking into account any of the aforementioned associated risks. Until more 
robust clinical and economic data becomes available, we suggest that provision of 
stimulated IUI, in centres where a satisfactory live birth rate is achieved, represents a 
significant cost-saving to those commissioning fertility services, with lower risks than IVF 
and an improvement on providing no treatment.  
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Table 1. Pregnancies per treatment cycle of IUI treatment undertaken with partner sperm, started in the 
calendar year 2013 (http://guide.hfea.gov.uk/guide/). 
 
 
 Age National Average Pregnancy Rate Under 35 11.8% 
35-37 13.2% 
38-39 10.1% 
40-42 5.0% 
43-44 3.9% 
